Health Canada

Questions and answers regarding the uses of risiloxane, 1,1,1,5,5,5-hexamethyl-3,3-bis[(trimethylsilyl)oxy]-(M4Q) and actions taken to protect the public and the environment.

Questions and answers regarding the uses of 1-Naphthalenemethanol, α,α-bis[4-(dimethylamino)phenyl]-4-(phenylamino)- (Solvent Blue 4) and actions taken to protect the public and the environment.

Questions and answers regarding the uses of 1-Naphthalenemethanol, α,α-bis[4-(diethylamino)phenyl]-4-(ethylamino)-( Solvent Blue ) and actions taken to protect the public and the environment.

Questions and answers regarding the uses of 1-Naphthalenol, 4-[(4-ethoxyphenyl)azo] (Solvent Red 3) and actions taken to protect the public and the environment.

Questions and answers regarding the uses of Methanesulfonamide, N-[2-[(2,6-dicyano-4-methylphenyl)azo]-5-(dipropylamino)phenyl] (DADM) and actions taken to protect the public and the environment.

Questions and answers regarding the uses of Isophorone and actions taken to protect the public and the environment.

Questions and answers regarding the uses of Michler's ketone and actions taken to protect the public and the environment.

Questions and answers regarding the uses of 2-Butanone, oxime and actions taken to protect the public and the environment.

The table compiles the proposed risk management actions for both health and the environment and provides the current status and any updated information for these proposed actions.

Follow these simple tips to stay safe while driving or working in your garage.

The Government of Canada makes regulations and develops guidelines and plans that apply across the whole country. It also leads in conducting scientific research on human health and environmental issues, and makes agreements with other countries, so that our laws provide the same or better level...

The substances listed below link to tables that outline the proposed risk management actions for those chemical substances in the Challenge that have met one or more criteria in section 64 of the Canadian Environmental Protection Act, 1999.

This dataset provides the results obtained by Health Canada’s Radiological Monitoring Network (CRMN) for the tritium activity concentration in drinking water originating from the water treatment plants in Ottawa, ON. More information about the CRMN network can be found on the Health Canada...

Arsenic is naturally occurring in the environment, and very low levels are present in various foods. Elevated arsenic exposure from drinking water has been associated with a variety of serious adverse health effects, with potential effects noted in vulnerable populations such as infants and...

Arsenic is naturally occurring in the environment, and very low levels are present in various foods. Elevated arsenic exposure from drinking water has been associated with a variety of serious adverse health effects, with potential effects noted in vulnerable populations such as infants and...

This dataset provides the background radiation dose results from Health Canada’s Canadian Radiological Monitoring Network (CRMN) monitoring sites. More information about the CRMN network can be found on the Health Canada website (see link below). This background radiation data contains both...

This dataset provides the results obtained by Health Canada’s Canadian Radiological Monitoring Network (CRMN) for the gross alpha and beta activity concentrations in drinking water, given in units of becquerels per liter (Bq/L). More information about the CRMN network can be found on the Health...

This dataset provides the results obtained by Health Canada’s Radiological Monitoring Network (CRMN) for tritium content in atmospheric water vapor sampled from monitoring stations in Ontario, Quebec and New Brunswick. More information about the CRMN network can be found on the Health Canada...

This document provides guidance to vaccine manufacturers seeking authorization for their vaccine that targets the SARS-CoV-2 virus. This guidance applies to applications under the interim order respecting the importation, sale and advertising of drugs for use in relation to COVID-19.

This document provides guidance to drug manufacturers seeking authorization for their drug manufactured, sold, or represented for use in relation to COVID-19. The guidance explains recent changes to the regulatory process for new COVID-19 drugs.